{"product_id":"biosimilars-market-by-drug-class-drug-class-monoclonal-antibodies-adalimumab-infliximab-rituximab-trastuzumab-insulin-erythropoietin-anticoagulants-rhgh-indication-region-global-forecast-to-2028","title":"Biosimilars Market by Drug Class (Drug Class (Monoclonal Antibodies (Adalimumab, Infliximab, Rituximab, Trastuzumab), Insulin, Erythropoietin, Anticoagulants. rhGH), Indication, Region – Global Forecast to 2028","description":"\u003cp\u003eBiosimilars Market by Drug Class (Drug Class (Monoclonal Antibodies (Adalimumab, Infliximab, Rituximab, Trastuzumab), Insulin, Erythropoietin, Anticoagulants. rhGH), Indication, Region – Global Forecast to 2028\u003c\/p\u003e\n\n\u003cp\u003eThe global biosimilars market size is projected to reach USD 66.9 billion by 2028 from USD 29.4 billion in 2023, at a CAGR of 17.8% during the forecast period. Factors such as regulatory approvals, favorable reimbursement policies, rising demand for cost effective biosimilars is driving the market growth.\u003c\/p\u003e \n\n\u003cp\u003e“The monoclonal antibodies product segment accounted for the highest growth rate in the biosimilars market, by drug class, during the forecast period”\u003c\/p\u003e\n\n\u003cp\u003eIn 2022, the monoclonal antibodies product segment accounted for the largest share of the biosimilars market, mainly due to the low prices of biosimilar monoclonal antibodies compared to the reference drugs and increased adoption of labs in the the treatment of cancer, autoimmune disorders, and osteoporosis. The growth of the fastest-growing segment was attributed to the rising incidence of cancer and chronic diseases globally. Increased approval for interchangeability insulin is likely to have positive impact on market.\u003c\/p\u003e \n\n\u003cp\u003e“Oncology segment accounted for the largest share of the indication segment in 2022.”\u003c\/p\u003e\n\n\u003cp\u003eBased on the indication, the biosimilars market is segmented into oncology, inflammatory and autoimmune diseases,  chronic diseases, blood disorders, growth hormone deficiency, infectious diseases, and other indications. Rising demand for cancer drugs, growth hormones across various regions is propelling the growth of the market.\u003c\/p\u003e \n\n\u003cp\u003e“Asia Pacific region is likely to grow at a faster pace.”\u003c\/p\u003e\n\n\u003cp\u003eThe biosimilars market is segmented into Europe, Asia Pacific, North America, latin America and Middle East and Africa. The APAC market is expected to be the fastest-growing regional segment during the forecast period due to the presence of numerous emerging players, less-stringent government regulations, and increasing cooperation among leading and regional players for development, manufacturing and commercialization of biosimilars.\u003c\/p\u003e\n\n\u003cp\u003eThe primary interviews conducted for this report can be categorized as follows:\u003c\/p\u003e\n\n\u003cp\u003eBy Respondent: Supply Side- 70%, and Demand Side - 30%\u003c\/p\u003e\n\n\u003cp\u003eBy Designation (Supply Side): Managers - 45%, CXOs \u0026amp; Directors - 30%, Executives- 25%\u003c\/p\u003e\n\n\u003cp\u003eBy Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, and Middle East and Africa -5%\u003c\/p\u003e\n\n\u003cp\u003eLists of Companies Profiled in the Report:\u003c\/p\u003e\n\n\u003cp\u003eNovartis AG (Switzerland)\u003c\/p\u003e\n\n\u003cp\u003ePfizer Inc. (US)\u003c\/p\u003e\n\n\u003cp\u003eDr. Reddy’s Laboratories Ltd. (India)\u003c\/p\u003e\n\n\u003cp\u003eF. Hoffmann-La Roche Ltd (Switzerland)\u003c\/p\u003e\n\n\u003cp\u003eEli Lilly \u0026amp; Company (US)\u003c\/p\u003e\n\n\u003cp\u003eAmgen Inc. (US)\u003c\/p\u003e\n\n\u003cp\u003eTeva Pharmaceutical Industries Ltd. (Israel)\u003c\/p\u003e\n\n\u003cp\u003eSamsung Biologics (South Korea)\u003c\/p\u003e\n\n\u003cp\u003eFresenius SE \u0026amp; Co. KGaA (Germany)\u003c\/p\u003e\n\n\u003cp\u003eBoehringer Ingelheim International GmbH. (Germany)\u003c\/p\u003e\n\n\u003cp\u003eSTADA Arzneimittel AG (Germany)\u003c\/p\u003e\n\n\u003cp\u003eCoherus BioSciences (US)\u003c\/p\u003e\n\n\u003cp\u003eFUJIFILM Kyova Kirin Biologics Co., Ltd. (Japan)\u003c\/p\u003e\n\n\u003cp\u003eUSV Limited (India),\u003c\/p\u003e\n\n\u003cp\u003eAmneal Pharmaceuticals LLC. (US)\u003c\/p\u003e\n\n\u003cp\u003eCelltrion Healthcare (South Korea)\u003c\/p\u003e\n\n\u003cp\u003eBiocon (India)\u003c\/p\u003e\n\n\u003cp\u003eIntas Pharmaceuticals Ltd. (India)\u003c\/p\u003e\n\n\u003cp\u003eReliance Life Sciences (India)\u003c\/p\u003e\n\n\u003cp\u003eAMEGA Biotech (Argentina)\u003c\/p\u003e\n\n\u003cp\u003eApotex, Inc. (Canada)\u003c\/p\u003e\n\n\u003cp\u003eBIOCAD (Russia)\u003c\/p\u003e\n\n\u003cp\u003emAbxience (Spain)\u003c\/p\u003e\n\n\u003cp\u003eProbiomed (Mexico)\u003c\/p\u003e\n\n\u003cp\u003eKashiv BioSciences, LLC (US),\u003c\/p\u003e\n\n\u003cp\u003eFormycon AG (Germany)\u003c\/p\u003e\n\n\u003cp\u003ePolpharma Biologics Group (Poland)\u003c\/p\u003e\n\n\u003cp\u003eAmphastar Pharmaceuticals, Inc. (US)\u003c\/p\u003e\n\n\u003cp\u003eAlvotech (Iceland)\u003c\/p\u003e\n\n\u003cp\u003eUCB SA, (Belgium)\u003c\/p\u003e\n\n\u003cp\u003eResearch Coverage:\u003c\/p\u003e\n\n\u003cp\u003eThis report provides a detailed picture of the biosimilars market. It aims at estimating the size and future growth potential of the market across different segments, such as drug class, indication and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.\u003c\/p\u003e\n\n\u003cp\u003eKey Benefits of Buying the Report:\u003c\/p\u003e\n\n\u003cp\u003eThe report will help market leaders\/new entrants by providing them with the closest approximations of the revenue numbers for the overall biosimilars market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.\u003c\/p\u003e\n\n\u003cp\u003eThe report provides insights on the following pointers:\u003c\/p\u003e \n\n\u003cp\u003eAnalysis of key drivers (Increasing demand for biosimilars, launch of novel biosimilars, rising geriatric population \u0026amp; chronic disease incidence, abbreviated regulatory process \u0026amp; interchangeability), restraints (complexities in manufacturing), opportunities (emerging markets, patent expiry of blockbuster biologics and research on new indication), and challenges (excess competition \u0026amp; regulatory challenges) influencing the growth of biosimilars market.\u003c\/p\u003e\n\n\u003cp\u003eProduct Development\/Innovation: Detailed insights on newly launched products, and pipeline analysis of the biosimilars market.\u003c\/p\u003e\n\n\u003cp\u003eMarket Development: Comprehensive information about lucrative markets – the report analyses the biosimilars market across varied regions.\u003c\/p\u003e \n\n\u003cp\u003eMarket Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the biosimilars market.\u003c\/p\u003e \n\n\u003cp\u003eCompetitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like Novartis AG (Switzerland), Pfizer Inc. (US), Dr. Reddy’s Laboratories Ltd. (India), F. Hoffmann-La Roche Ltd (Switzerland), Eli Lilly \u0026amp; Company (US), Amgen Inc. (US) and  among others in the biosimilars market.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"June, 2023 \/ 298 Pages \/ MCW16230690","offer_id":47647151980850,"sku":null,"price":5940.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/biosimilars-market-by-drug-class-drug-class-monoclonal-antibodies-adalimumab-infliximab-rituximab-trastuzumab-insulin-erythropoietin-anticoagulants-rhgh-indication-region-global-forecast-to-2028","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}